Biogen CEO Discusses Tumultuous Aduhelm Launch

Biogen CEO Michel Vounatsos recently shared his thoughts regarding the hectic Aduhelm launch at the Morgan Stanley 19th Annual Global Healthcare Conference. The drug’s high price tag, unclear efficacy data, and lack of coverage by payers continue to make waves throughout the pharmaceutical industry.

According to the CEO, there’s “clearly too much confusion, misinformation and controversy surrounding our data and the approval process.” Read more here.

(Source: Eric Sagonowsky, Fierce Pharma, 9/9/21)